Edition:
United Kingdom

Teligent Inc (TLGT.OQ)

TLGT.OQ on NASDAQ Stock Exchange Global Select Market

3.82USD
3:40pm GMT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.82
Open
$3.80
Day's High
$3.84
Day's Low
$3.52
Volume
31,840
Avg. Vol
152,076
52-wk High
$9.53
52-wk Low
$2.82

Latest Key Developments (Source: Significant Developments)

TELIGENT ANNOUNCES FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%.TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%.TELIGENT INC- ‍EXPECT TO LAUNCH HYDROCORTISONE BUTYRATE LOTION 0.1%​ IN Q1 OF 2018.  Full Article

TELIGENT ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Teligent Inc ::TELIGENT, INC. ANNOUNCES FDA APPROVAL OF ERYTHROMYCIN TOPICAL SOLUTION USP, 2%.TELIGENT INC- ‍EXPECT TO LAUNCH ERYTHROMYCIN TOPICAL SOLUTION USP, 2% BEFORE THE END 2017.  Full Article

Teligent announces FDA approval of betamethasone dipropionate ointment usp (augmented), 0.05%​
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Teligent Inc ::Announces FDA approval of betamethasone dipropionate ointment USP (augmented), 0.05%​.Expect to launch betamethasone dipropionate ointment USP (augmented), 0.05% in Q1 of 2018​.  Full Article

Teligent posts Q3 qtrly ‍loss per share $0.12​
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Teligent Inc :Teligent Inc announces third quarter 2017 results.Sees FY 2017 revenue $65 million to $67 million.Q3 revenue fell 15 percent to $13.7 million.Teligent Inc qtrly ‍loss per share $0.12​.Q3 earnings per share view $-0.01, revenue view $19.1 million -- Thomson Reuters I/B/E/S.Teligent Inc - ‍now anticipates gross margin of 38% to 40% for year ending december 31, 2017​.Teligent - Q3 ‍results, revised FY outlook due to knock-on effect of ANDA approval delays, increased competition in one of our largest products​.  Full Article

Teligent opens a product development laboratory in Estonia
Tuesday, 11 Oct 2016 

Teligent Inc :Opened a pharmaceutical product development laboratory in Estonia.  Full Article

Teligent says Health Canada approves 3 baclofen injection products
Thursday, 25 Aug 2016 

Teligent Inc : Teligent Inc announces Health Canada approval of three baclofen injection products . Says based on internal estimates, total addressable market for these products are approximately $1.0 million CAD .Says groups are now preparing for launch of these three products in early 2017.  Full Article

Teligent Inc announces Q2 2016 results
Thursday, 28 Jul 2016 

Teligent Inc : Says expects total revenue between $65.0 and $72.0 million for year ended December 31, 2016 . Teligent Inc says intends to submit at least 15 ANDAs with FDA in 2016 . Says anticipates gross margin of 54% to 56% for year ended December 31, 2016 . Qtrly loss per share $0.05 . FY2016 revenue view $65.7 million -- Thomson Reuters I/B/E/S . Teligent, Inc. announces second quarter 2016 results . Sees FY 2016 revenue $65 million to $72 million . Q2 revenue rose 93 percent to $17.1 million . Q2 adjusted earnings per share $0.02 . Teligent Inc says expects to spend between 28% and 32% of total revenue in research and development by end of 2016 . Says expects operating income between $2.0 and $4.0 million for year ended December 31, 2016 .Q2 earnings per share view $-0.02, revenue view $16.0 million -- Thomson Reuters I/B/E/S.  Full Article

Teligent announces FDA approval of triamcinolone acetonide ointment
Monday, 16 May 2016 

Teligent Inc :Teligent, Inc announces FDA approval of triamcinolone acetonide ointment usp, 0.1%.  Full Article

Horizon Pharma says settles patent litigation with Teligent
Thursday, 12 May 2016 

Horizon Pharma Plc : Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc. .Says granted Teligent non-exclusive right to market a generic diclofenac sodium topical 2 pct w/w solution in United States.  Full Article

Teligent Inc ( IGI Laboratories ) announces FDA approval of desoximetasone ointment USP 0.25%
Friday, 26 Feb 2016 

Teligent Inc ( IGI Laboratories ):Has received approval of the company's abbreviated new drug application from U.S. food and drug administration of desoximetasone ointment USP 0.25%.Expects to launch desoximetasone ointment USP 0.25% in 15g, 60g and 100g tubes in the second quarter of 2016.  Full Article

BRIEF-TELIGENT ANNOUNCES FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%

* TELIGENT, INC. ANNOUNCES FIRST FDA GENERIC APPROVAL OF HYDROCORTISONE BUTYRATE LOTION 0.1%